Drug Profile
Research programme: cathepsin S inhibitors - Bayer Schering Pharma
Latest Information Update: 24 Mar 2010
Price :
$50
*
At a glance
- Originator Celera Genomics Group
- Developer Bayer Schering Pharma
- Class
- Mechanism of Action Cathepsin S inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG
- 27 Jun 2006 Schering has acquired the cathepsin S inhibitors research programme from Celera Genomics
- 21 Sep 2005 Preclinical trials in Autoimmune disorders in USA (unspecified route)